Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Vaccine. 2019 May 1;37(19):2529-2531. doi: 10.1016/j.vaccine.2019.03.030. Epub 2019 Apr 5.

Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study.

Author information

1
Valneva Austria GmbH, Campus Vienna Biocenter, Vienna, Austria. Electronic address: christian.taucher@valneva.com.
2
Department of Specific Prophylaxis and Tropical Medicine at the Institute of Pathophysiology, Medical University Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria.
3
Valneva Austria GmbH, Campus Vienna Biocenter, Vienna, Austria.

Abstract

Immunization with the Japanese encephalitis (JE) vaccine IXIARO® results in protective neutralizing antibody levels for one year. Since persistence of protective titer levels beyond one year was unknown, a 5 years follow-up study was conducted. Additionally, data were stratified to compare the persistence of protective neutralizing antibodies against JE in people with or without tick-borne encephalitis (TBE) vaccination. Four weeks after the primary series, the percentage of subjects with PRNT50 titer ≥1:10 in the intent-to-treat population was 99%; the rate after 5 years was 81.6%. By month 24, 36, 48 and 60, the percentages were still 90.7%, 91.7%, 90.1%, 85.9%, respectively in the population who had received TBE vaccine compared to 67.9%, 71.9%, 69.1%, 63.8% in the population who had not. No long-term safety concerns were identified. These data indicate that vaccination with IXIARO® is able to induce protective titers that persist up to 60 months after the primary immunization. Clinical trial registry number NCT00596102.

KEYWORDS:

IC51; IXIARO®; Immunogenicity; Japanese encephalitis; Safety; Seroprotection; Traveler

PMID:
30962094
DOI:
10.1016/j.vaccine.2019.03.030
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center